ELISA Kit for Procollagen I C-Terminal Propeptide (PICP) 
P1CP; C-Propeptide Of Type I Procollagen; Procollagen I Carboxy Terminal Propeptide
- UOM
- FOB US$ 454.00 US$ 648.00 US$ 2,916.00 US$ 5,508.00 US$ 45,360.00
- Quantity
Overview
Properties
- Product No.CEA570Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- ApplicationsEnzyme-linked immunosorbent assay for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryMetabolic pathwayHepatologyBone metabolism
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Procollagen I C-Terminal Propeptide (PICP) and the recovery rates were calculated by comparing the measured value to the expected amount of Procollagen I C-Terminal Propeptide (PICP) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 85-92 | 88 |
| EDTA plasma(n=5) | 92-99 | 95 |
| heparin plasma(n=5) | 96-105 | 102 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Procollagen I C-Terminal Propeptide (PICP) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Procollagen I C-Terminal Propeptide (PICP) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Procollagen I C-Terminal Propeptide (PICP) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 83-95% | 92-105% | 97-104% | 80-92% |
| EDTA plasma(n=5) | 78-97% | 83-91% | 85-101% | 81-103% |
| heparin plasma(n=5) | 78-101% | 87-96% | 78-101% | 87-103% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
| Standard | 2 | Standard Diluent | 1×20mL |
| Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
| Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
| TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
| Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well.
And then add 50µL prepared Detection Reagent A immediately.
Shake and mix. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
5. Aspirate and wash 5 times;
6. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
7. Add 50µL Stop Solution. Read at 450 nm immediately.
Test principle
This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Procollagen I C-Terminal Propeptide (PICP) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Procollagen I C-Terminal Propeptide (PICP) and unlabeled Procollagen I C-Terminal Propeptide (PICP) (Standards or samples) with the pre-coated antibody specific to Procollagen I C-Terminal Propeptide (PICP). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Procollagen I C-Terminal Propeptide (PICP) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Procollagen I C-Terminal Propeptide (PICP) in the sample.
Giveaways
Increment services
Citations
- Dyslipidemic high-fat diet affects adversely bone metabolism in mice associated with impaired antioxidant capacityScienceDirect: S0899900709004717
- Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure.PubMed: 23067911
- Circulating biomarkers of collagen metabolism in arterial hypertension: relevance of target organ damagePubmed: 23615327
- Cdkn1a is a key mediator of rat pancreatic stellate cell senescencePubmed: 23719597
- Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry diseasePubmed:25073565
- An NMR Metabolomic Study on the Effect of Alendronate in Ovariectomized MicePubmed:25184758
- The Anti-Osteoanabolic Function of Sclerostin is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5Pubmed:25640331
- The active role of osteoporosis in the interaction between osteoblasts and bone metastasesPubMed: 26057367
- Consumption of vitamin D2PubMed: 25792284
- Bilaterale Kommunikation zwischen Osteoblasten und Osteoklastenvolltexte:2016
- Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathypubmed:27516211
- Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRRpubmed:28004175
- The association between insulin-like growth factor 1 (IGF-1), IGF-binding proteins (IGFBPs), and the carboxyterminal propeptide of type I procollagen (PICP) in pre- and postmenopausal women with rheumatoid arthritis.pubmed:27775453
- Effect of montelukast on markers of airway remodeling in children withasthma.pubmed:27657514
- The association between insulin-like growth factor 1 (IGF-1), IGF-binding proteins (IGFBPs), and the carboxyterminal propeptide of type I procollagen (PICP) in pre- and postmenopausal women with rheumatoid arthritisloi:irhe20
- Conditional Mouse Models Support the Role of SLC39A14 (ZIP14) in Hyperostosis Cranialis Interna and in Bone HomeostasisISBN: 978-94-6299-582-6
- Endothelial‑to‑mesenchymal transition in human idiopathic dilated cardiomyopathypubmed:29115553
- Age-related changes in biochemical bone profile in thalassemic childrenpubmed:28967496
- Left ventricular reverse remodeling is not related to biopsy‑detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR10.1007/s00380-016-0930-y
- The Lrp4 R1170Q homozygous knock‐in mouse recapitulates the bone phenotype of sclerosteosis in humanspubmed:28477420
- 12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis.pubmed:28460256
- Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events.pubmed:29120858
- Mutations That Alter the Carboxy‐Terminal‐Propeptide Cleavage Site of the Chains of Type I Procollagen Are Associated With a Unique Osteogenesis Imperfecta …Pubmed:29669177
- Assessment of myocardial fibrosis by late gadolinium enhancement imaging and biomarkers of collagen metabolism in chronic rheumatic mitral regurgitation.Pubmed:29443354
- DNA methylation regulates α‐smooth muscle actin expression during cardiac fibroblast differentiationPubmed: 30362530
- Altered serum levels of type I collagen turnover indicators accompanied by IL-6 and IL-8 release in stable COPDPubmed: 30655663
- Low fibrosis biomarker levels predict cardiac resynchronization therapy responsePubmed: 30988339
- Agonist-induced activation of the S1P receptor 2 constitutes a novel osteoanabolic therapy for the treatment of osteoporosis in micePubmed: 31028959
- Deficiency of sphingosine-1-phosphate receptor 3 does not affect the skeletal phenotype of mice lacking sphingosine-1-phosphate lyasePubmed: 31314788
- Mice lacking plastin-3 display a specific defect of cortical bone acquisitionPubmed: 31678489
- Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of FibrosisPubmed: 33224989
- Piezo1 Inactivation in Chondrocytes Impairs Trabecular Bone FormationPubmed: 33180356
- Microbiome changes in patients with chronic heart failure with preserved ejection fraction correlate with fibrosis markers: Description of a Russian cohort
- Ассоциации толщины эпикардиального жира и циркулирующих маркеров фиброза миокарда у пациентов с инфарктом миокарда
- Early diagnosis of myocardial fibrosis in patients with epicardial obesity
- Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus34778465
- Extra Cellular Matrix Deposition and Assembly in Dermis Spheroids34321901
- Dual integrin αvβ3 and αvβ5 blockade attenuates cardiac dysfunction by reducing fibrosis in a rat model of doxorubicin-induced cardiomyopathy34296634
- Effects of 8-week increment aerobic exercise program on bone metabolism and body composition in young non-athletesPubmed:35141785
- Simple Predictors for Cardiac Fibrosis in Patients with Type 2 Diabetes Mellitus: The Role of Circulating Biomarkers and Pulse Wave VelocityPubmed:35628969